You are here: Industry Insights > GlaxoSmithKline

News List

GlaxoSmithKline mulls respiratory exit to support big bet on cancer R&D fiercebiotech
November 02, 2018
GlaxoSmithKline may exit the respiratory business and pull back in other areas to commit more cash to cancer R&D, according to Axel Hoos. Hoos, GSK’s head of oncology, ...
Orchard Therapeutics’ war chest balloons with $200M IPO fiercebiotech
November 02, 2018
Orchard Therapeutics priced its IPO at $14 a share, raising $200 million and exceeding the $173 million goal it set earlier this month. The funds will bankroll the pivotal trials and...
GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply fiercepharma
November 01, 2018
GlaxoSmithKline's Shingrix zooms toward blockbuster status despite tight supply
GSK announces results of three year trial into long-lasting HIV injection pharmafile
October 31, 2018
GlaxoSmithKline have announced the results of a three year investigation into a long acting, injectable, two-drug HIV regimen at the HIV Glasgow Drug Therapy meeting in Scotland.
GlaxoSmithKline expands API production for COPD inhalers as Advair sales wither fiercepharma
October 24, 2018
Even with looming generic competition expected to take a big bite out of sales of its blockbuster Advair, respiratory drugs remain key to GlaxoSmithKline, and it continues to plow money into their production.
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital fiercepharma
October 19, 2018
Merck joins Novartis, GlaxoSmithKline in grabbing a consumer executive to beef up digital
GSK to axe 99 positions at Memphis site pharmafile
October 19, 2018
GlaxoSmithKline’s workforce on President’s Island in Memphis, US, is set to see the loss of 99 employees, as revealed in a WARN notice filed with the State Department of Labor.
EMA, MHRA and GlaxoSmithKline blast BMJ’s ‘flawed’ pandemic flu vaccine safety report fiercepharma
September 29, 2018
The EMA, MHRA and GSK criticized a BMJ report that suggests Pandemrix is less safe as scientifically “flawed and misleading.”
GlaxoSmithKline sharpens ax for 650 job cuts—450 in sales—to channel money toward new launches, R&D fiercepharma
September 28, 2018
After a business review unveiled in July—and ahead of new challenges—GlaxoSmithKline is sharpening its jobs ax to cut 650 across its U.S. business. On the block are 450 field sales positions, plus another 100 each at its ...
GlaxoSmithKline fails to warn of pandemic flu vaccine’s alarming safety signal fiercepharma
September 21, 2018
GlaxoSmithKline’s H1N1 swine flu vaccine Pandemrix made waves around 2010 after increased cases of narcolepsy emerged in Sweden and Finland among children who got it during the previous pandemic.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page